VectorY enters agreement with Shape Therapeutics for AAV capsid
VectorY Therapeutics has signed an agreement securing an exclusive option to assess Shape Therapeutics’ SHP-DB1 adeno-associated virus (AAV) capsid for …
Post
-
-
FDA ends HAE drought with record year of approvals
After four years of inactivity, the US Food and Drug Administration (FDA) approved three novel products for hereditary angiooedema (HAE) …
-
EASD 2025: NA-931 establishes excellent efficacy and safety in obese patients
At the European Association for the Study of Diabetes (EASD) Annual Meeting 2025, findings from a Phase II clinical trial …
-
Biogen’s Zurzuvae approved as first postpartum depression drug in Europe
Millions of parents in Europe who suffer from postpartum depression will now have access to a pharmaceutical treatment, following the …
-
Roche signs agreement to acquire 89bio in $2.4bn deal
Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a total equity value …
-
As US funding falters, mRNA cancer vaccine pioneers face new hurdles
Cuts to mRNA vaccine funding in the US have stalled infectious disease programmes, with experts warning the consequences are likely …
-
EASD 2025: miR-155 upregulation in pancreas spotlights new T1D targets
At the 2025 European Association for the Study of Diabetes meeting in Vienna, University of Bremen investigators reported that microRNA‑155 …
-
EASD 2025: REDEFINE 2 trial unveils meaningful weight reduction with CagriSema
At the European Association for the Study of Diabetes (EASD) Annual Meeting 2025, findings were shown from the Phase IIIa …
-
EASD 2025: Viperin signals a path to targeted beta‑cell preservation in T1D
At the 2025 European Association for the Study of Diabetes meeting in Vienna, University of Dundee researchers reported that Viperin …
-
Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small interfering …
-
EASD 2025: Early UK screening for T1D shows real-world readiness
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported that the Early Surveillance …
-
EASD 2025: SAB-142 Phase I data demonstrates novel T1D immunotherapy
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, SAB Biotherapeutics presented Phase 1 data …
-
Big pharma companies hit with FDA warning letters in drug ad clampdown
The US Food and Drug Administration (FDA) has followed up on its promise to clampdown on misleading and deceptive drug …
-
EASD 2025: Zimislecel infusion advances insulin independence in T1D
At the 2025 European Association for the Study of Diabetes (EASD) meeting in Vienna, investigators reported one-year outcomes from FORWARD, …
-
Solving global CDMO challenges: Indena and TCG GreenChem’s strategic-alliance
Contract development and manufacturing organisations (CDMOs) are facing mounting pressures to streamline production processes while adhering to increasingly stringent quality …
